131 related articles for article (PubMed ID: 23931439)
1. From the multifactorial nature of Alzheimer`s disease to multitarget therapy: the contribution of the translational approach.
Calzà L; Baldassarro VA; Giuliani A; Lorenzini L; Fernandez M; Mangano C; Sivilia S; Alessandri M; Gusciglio M; Torricella R; Giardino L
Curr Top Med Chem; 2013; 13(15):1843-52. PubMed ID: 23931439
[TBL] [Abstract][Full Text] [Related]
2. 1-(3',4'-Dichloro-2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic acid (CHF5074), a novel gamma-secretase modulator, reduces brain beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease without causing peripheral toxicity.
Imbimbo BP; Del Giudice E; Colavito D; D'Arrigo A; Dalle Carbonare M; Villetti G; Facchinetti F; Volta R; Pietrini V; Baroc MF; Serneels L; De Strooper B; Leon A
J Pharmacol Exp Ther; 2007 Dec; 323(3):822-30. PubMed ID: 17895400
[TBL] [Abstract][Full Text] [Related]
3. The γ-secretase modulator CHF5074 restores memory and hippocampal synaptic plasticity in plaque-free Tg2576 mice.
Balducci C; Mehdawy B; Mare L; Giuliani A; Lorenzini L; Sivilia S; Giardino L; Calzà L; Lanzillotta A; Sarnico I; Pizzi M; Usiello A; Viscomi AR; Ottonello S; Villetti G; Imbimbo BP; Nisticò G; Forloni G; Nisticò R
J Alzheimers Dis; 2011; 24(4):799-816. PubMed ID: 21321397
[TBL] [Abstract][Full Text] [Related]
4. Dual inhibitors of β-amyloid aggregation and acetylcholinesterase as multi-target anti-Alzheimer drug candidates.
Viayna E; Sabate R; Muñoz-Torrero D
Curr Top Med Chem; 2013; 13(15):1820-42. PubMed ID: 23931440
[TBL] [Abstract][Full Text] [Related]
5. Multifunctional tacrine derivatives in Alzheimer's disease.
Minarini A; Milelli A; Simoni E; Rosini M; Bolognesi ML; Marchetti C; Tumiatti V
Curr Top Med Chem; 2013; 13(15):1771-86. PubMed ID: 23931443
[TBL] [Abstract][Full Text] [Related]
6. [Therapy of Alzheimer disease].
Kovács T
Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
[TBL] [Abstract][Full Text] [Related]
7. Interacting with γ-secretase for treating Alzheimer's disease: from inhibition to modulation.
Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
Curr Med Chem; 2011; 18(35):5430-47. PubMed ID: 22087836
[TBL] [Abstract][Full Text] [Related]
8. CHF5074 and LY450139 sub-acute treatments differently affect cortical extracellular glutamate levels in pre-plaque Tg2576 mice.
Beggiato S; Giuliani A; Sivilia S; Lorenzini L; Antonelli T; Imbimbo BP; Giardino L; Calzà L; Ferraro L
Neuroscience; 2014 Apr; 266():13-22. PubMed ID: 24530449
[TBL] [Abstract][Full Text] [Related]
9. CHF5074 (CSP-1103) induces microglia alternative activation in plaque-free Tg2576 mice and primary glial cultures exposed to beta-amyloid.
Porrini V; Lanzillotta A; Branca C; Benarese M; Parrella E; Lorenzini L; Calzà L; Flaibani R; Spano PF; Imbimbo BP; Pizzi M
Neuroscience; 2015 Aug; 302():112-20. PubMed ID: 25450955
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic effect of CHF5074, a new γ-secretase modulator, in a mouse model of scrapie.
Poli G; Corda E; Lucchini B; Puricelli M; Martino PA; Dall'ara P; Villetti G; Bareggi SR; Corona C; Vallino Costassa E; Gazzuola P; Iulini B; Mazza M; Acutis P; Mantegazza P; Casalone C; Imbimbo BP
Prion; 2012; 6(1):62-72. PubMed ID: 22453180
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo profiling of CHF5022 and CHF5074 Two beta-amyloid1-42 lowering agents.
Imbimbo BP; Del Giudice E; Cenacchi V; Volta R; Villetti G; Facchinetti F; Riccardi B; Puccini P; Moretto N; Grassi F; Ottonello S; Leon A
Pharmacol Res; 2007 Apr; 55(4):318-28. PubMed ID: 17292621
[TBL] [Abstract][Full Text] [Related]
12. CHF5074 reduces biomarkers of neuroinflammation in patients with mild cognitive impairment: a 12-week, double-blind, placebo-controlled study.
Ross J; Sharma S; Winston J; Nunez M; Bottini G; Franceschi M; Scarpini E; Frigerio E; Fiorentini F; Fernandez M; Sivilia S; Giardino L; Calza L; Norris D; Cicirello H; Casula D; Imbimbo BP
Curr Alzheimer Res; 2013 Sep; 10(7):742-53. PubMed ID: 23968157
[TBL] [Abstract][Full Text] [Related]
13. Emerging targets in neurodegeneration: new opportunities for Alzheimer's disease treatment?
Rampa A; Gobbi S; Belluti F; Bisi A
Curr Top Med Chem; 2013; 13(15):1879-904. PubMed ID: 23931436
[TBL] [Abstract][Full Text] [Related]
14. Tarenflurbil: a shot on goal.
Aisen PS
Lancet Neurol; 2008 Jun; 7(6):468-9. PubMed ID: 18450518
[No Abstract] [Full Text] [Related]
15. CHF5074, a novel gamma-secretase modulator, restores hippocampal neurogenesis potential and reverses contextual memory deficit in a transgenic mouse model of Alzheimer's disease.
Imbimbo BP; Giardino L; Sivilia S; Giuliani A; Gusciglio M; Pietrini V; Del Giudice E; D'Arrigo A; Leon A; Villetti G; Calzà L
J Alzheimers Dis; 2010; 20(1):159-73. PubMed ID: 20164581
[TBL] [Abstract][Full Text] [Related]
16. Transgenic AD model mice, effects of potential anti-AD treatments on inflammation and pathology.
van Groen T; Kadish I
Brain Res Brain Res Rev; 2005 Apr; 48(2):370-8. PubMed ID: 15850676
[TBL] [Abstract][Full Text] [Related]
17. Drug pipeline in neurodegeneration based on transgenic mice models of Alzheimer's disease.
Li C; Ebrahimi A; Schluesener H
Ageing Res Rev; 2013 Jan; 12(1):116-40. PubMed ID: 22982398
[TBL] [Abstract][Full Text] [Related]
18. Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer's disease.
D'Onofrio G; Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Paroni G; Cascavilla L; Seripa D; Pilotto A
Expert Opin Drug Discov; 2012 Jan; 7(1):19-37. PubMed ID: 22468891
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic potential of gamma-secretase inhibitors and modulators.
Imbimbo BP
Curr Top Med Chem; 2008; 8(1):54-61. PubMed ID: 18220933
[TBL] [Abstract][Full Text] [Related]
20. Gamma-secretase as a pharmacological target in Alzheimer disease research: when, why and how?
Ziani-Cherif C; Mostefa-Kara B; Brixi-Gormat FZ
Curr Pharm Des; 2006; 12(33):4313-35. PubMed ID: 17105430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
